Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Previous studies from our laboratory indicate that intratumoral (i.t.) injections of CpG-ODN are the most effective adjuvant strategy to induce an antitumor immune response in tolerant BALB-neuT mice but insufficient for tumor eradication. We evaluated whether this treatment strategy could be enhanced by the presence of anti-OX40 and anti-4-1BB antibodies. Treatment with anti-4-1BB resulted in a greater antitumor response than anti-OX40. The results indicate that anti-4-1BB but not anti-OX40 inhibited the suppressive function of T regulatory cells (Tregs). Through microarray analysis we evaluated the mechanism by which anti-4-1BB inhibits iTregs using the Foxp3-GFP mice. We observed specific transcriptional differences in over 100 genes in iTregs treated with anti-4-1BB, and selected those genes that remained unaffected by exposure to anti-OX40. Interleukin 9 was transcriptionally down-regulated 28-fold by anti-4-1BB treatment, and this was matched by a significant reduction of IL-9 secretion by iTregs. Furthermore, blockade of the common γ-chain receptor resulted in the inhibition of iTreg-suppressive function. More importantly, neutralization of IL-9 plus i.t. injections of CpG-ODN induces tumor rejection in BALB-neuT and MUC-1 tolerant transgenic mice. These results indicate that IL-9 plays a role in iTreg biology during the tumor inflammatory process enhancing/promoting the suppressive function of these cells and that the blockade of IL-9 could serve as a novel strategy to modulate the function of Tregs to enhance the antitumor effect of tumor vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A function for interleukin 2 in Foxp3-expressing regulatory T cells
Fontenot, J. D., Rasmussen, J. P., Gavin, M. A., & Rudensky, A. Y. (2005) · Nature Immunology · doi:10.1038/ni1263 · Cited by 1,819
Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., & Stockinger, B. (2008) · Nature Immunology · doi:10.1038/ni.1659 · Cited by 1,213
Mast cells are essential intermediaries in regulatory T-cell tolerance
Lu, L.-F., Lind, E. F., Gondek, D. C., Bennett, K. A., Gleeson, M. W., Pino-Lagos, K., Scott, Z. A., Coyle, A. J., Reed, J. L., Van Snick, J., et al. (2006) · Nature · doi:10.1038/nature05010 · Cited by 751 · cited 1×
“9 [33] and indicate that iTregs secrete higher levels of IL-9 than nTregs, which is in agreement with previous studies indicating that TGF-b is a critical factor in promoting IL-9 production [34].”
ResultElyaman, W., Bradshaw, E. M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Bettelli, E., Oukka, M., van Snick, J., Renauld, J.-C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812530106 · Cited by 498 · cited 3×
“5) and the presence of IL-9 could help in expanding and maintaining the suppressive function of Tregs [35], we believe that IL-9 secreted by iTregs creates an autocrine feedback loop mechanism to maintain the number and suppressive function of Tregs.”
BackgroundIL-9 as a mediator of Th17-driven inflammatory disease
Nowak, E. C., Weaver, C. T., Turner, H., Begum-Haque, S., Becher, B., Schreiner, B., Coyle, A. J., Kasper, L. H., & Noelle, R. J. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090246 · Cited by 393
Townsend, M. J., Fallon, P. G., Matthews, D. J., Smith, P., Jolin, H. E., & McKenzie, A. N. J. (2000) · Immunity · doi:10.1016/s1074-7613(00)00056-x · Cited by 328 · cited 1×
“We do not think that IL-9 is critical for the development of Tregs since IL-9 KO mice have normal T cell development and the percentages of Tregs in these animals is similar as wild type mice [41], which is compatible with our in vitro inhibition assays.”
ResultSharma, S., Dominguez, A. L., Hoelzinger, D. B., & Lustgarten, J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0393-1 · Cited by 46 · cited 1×
“Previous studies from our group indicate that the levels of IL-2, IL-4, and IL-15 within the tumor are minimal [42] indicating that other mechanisms might exist within the tumor to maintain/expand the number and suppressive function of Tregs.”
BackgroundSelf-citation
Cited by
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Chester, C., Sanmamed, M. F., Wang, J., & Melero, I. (2018) · Blood · doi:10.1182/blood-2017-06-741041 · Cited by 499
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
The development and in vivo function of T helper 9 cells
Kaplan, M. H., Hufford, M. M., & Olson, M. R. (2015) · Nature Reviews Immunology · doi:10.1038/nri3824 · Cited by 384
Th9 cells promote antitumor immune responses in vivo
Lu, Y., Hong, S., Li, H., Park, J., Hong, B., Wang, L., Zheng, Y., Liu, Z., Xu, J., He, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65459 · Cited by 361
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Linch, S. N., McNamara, M. J., & Redmond, W. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00034 · Cited by 238
“OX86 CpG TUBO mammary No Delayed tumor progression; prolonged survival (62)”
Background
Metadata
- Authors
- Smith, S. E., Hoelzinger, D. B., Dominguez, A. L., Van Snick, J., & Lustgarten, J.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2011-07-26
- Volume
- 60
- Issue
- 12
- Pages
- 1775-1787
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2028120469
- Cited by
- 67
- References
- 7
- FWCI
- 1.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. https://app.cochat.ai/papers/10.1007/s00262-011-1075-6
- The paper
- Smith, S. E., Hoelzinger, D. B., Dominguez, A. L., Van Snick, J., & Lustgarten, J. (2011). Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-011-1075-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.